FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Higgons John Duncan (Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET (Street) CAMBRIDGE MA 02139						2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC [AGIO] 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2015 4. If Amendment, Date of Original Filed (Month/Day/Year)									ionship of Reporting Person(s) to Issuer all applicable) Director 10% Owner Officer (give title Other (specify below) below) Chief Operating Officer dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(Oily)	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye					ion 2 /Year) i	n 2A. Deemed Execution Da			3. Transa Code (I 8)	tion	4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			() or 5. Am		ount of ties cially	For (D) Indi	m: Direct or irect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price		Transa	ported ansaction(s) str. 3 and 4)			
Common stock 08/17/201						15			M ⁽¹⁾		20,000	0,000 A \$0)25	15	151,835		D	
Common stock 08/17/201					015	15			S ⁽²⁾		20,000	20,000 D \$9		4(3)	131,835			D	
		T	able I	II - Deriva (e.g., p							osed of converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any	eemed tion Date, h/Day/Year)	4. Transac Code (Ir 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Expirati (Month/	on D		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		of Der Sec	Price ivative urity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock option (right to buy)	\$0.3025	08/17/2015			M ⁽¹⁾			20,000	(4)		08/12/2019	Common stock	20,000	\$	0.00	285,022		D	

Explanation of Responses:

- $1. \ This \ exercise \ was \ effected \ pursuant \ to \ a \ Rule \ 10b5-1 \ trading \ plan \ adopted \ by \ the \ reporting \ person.$
- 2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 3. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of \$90.54 to \$93.58. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- 4. This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on June 13, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Glenn Goddard, as Attorney-in-Fact for John Duncan Higgons

08/19/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.